Polycystic ovary syndrome (PCOS);Le syndrome des ovaires polykystiques (SOPK)

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 36, Issue 5, 2007, Pages 423-446

  Torre, A ^a,b,c   Fernandez, H ^a,b,c,d  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

^c INSERM   (France)

^d INSTITUT NATIONAL D'ÉTUDES DÉMOGRAPHIQUES   (France)

Author keywords

Arterial hypertension; Chronic low dose protocol; Clomiphene citrate; Cyproterone acetate; Dyslipidemia; Endometrial cancer; Gonadotrophines; Hirsutism; Hyper androgenism; In vitro maturation of oocytes; Infertility by anovulation; Metabolic syndrome; Metformine; Ovarian hyper stimulation syndrome; Sleep apnea; SOPK; Type 2 diabetes

Indexed keywords

ANDROGEN; CLOMIFENE CITRATE; GONADOTROPIN; INSULIN;

ANOVULATION; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; FERTILIZATION IN VITRO; GLUCOSE INTOLERANCE; GYNECOLOGIC DISEASE; HIRSUTISM; HUMAN; INFERTILITY; INSULIN RESISTANCE; LOW DRUG DOSE; MENSTRUATION DISORDER; MULTIPLE PREGNANCY; NON INSULIN DEPENDENT DIABETES MELLITUS; OOCYTE MATURATION; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; PHYSICIAN; PREGNANCY DISORDER; RESPIRATORY TRACT DISEASE; REVIEW; RISK FACTOR; SLEEP APNEA SYNDROME; WEIGHT REDUCTION; WOMEN'S HEALTH; FEMALE; PHYSIOLOGY; REPRODUCTION;

FEMALE; HUMANS; INSULIN RESISTANCE; POLYCYSTIC OVARY SYNDROME; REPRODUCTION; RISK FACTORS;

EID: 34548151476     PISSN: 03682315     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jgyn.2007.04.002     Document Type: Review

References (260)

1. Adams J., Polson D.W., and Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br. Med. J. (Clin. Res. Ed.) 293 6543 (1986) 355-359
2. Carmina E., and Lobo R.A. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J. Clin. Endocrinol. Metab. 84 6 (1999) 1897-1899
3. Emperauger B., and Kuttenn F. Polycystic ovarian dystrophies. Diagnostic criteria and treatment. Presse Med. 24 18 (1995) 863-868
4. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril. 81 1 (2004) 19-25
5. Franks S. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. J. Clin. Endocrinol. Metab. 91 3 (2006) 786-789
6. Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J. Clin. Endocrinol. Metab. 91 3 (2006) 781-785
7. McDonough P.G. How many of the items in the polycystic ovary syndrome can be validated statistically?. Fertil. Steril. 85 2 (2006) 530-531
8. Dewailly D. How many of the items in the polycystic ovary syndrome can be validated statistically?. Fertil. Steril. 85 2 (2006) 529 [author reply 530]
9. Broekmans F.J., Knauff E.A., Valkenburg O., Laven J.S., Eijkemans M.J., and Fauser B.C. PCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG 113 10 (2006) 1210-1217
10. Dewailly D., Catteau-Jonard S., Reyss A.C., Leroy M., and Pigny P. Oligoanovulation with polycystic ovaries but not overt hyperandrogenism. J. Clin. Endocrinol. Metab. 91 10 (2006) 3922-3927
11. Gomel V., and Yarali H. Surgical treatment of polycystic ovary syndrome associated with infertility. Reprod. Biomed. Online 9 1 (2004) 35-42
12. Ehrmann D.A. Polycystic ovary syndrome. N. Engl. J. Med. 352 12 (2005) 1223-1236
13. Charnvises K., Weerakiet S., Tingthanatikul Y., Wansumrith S., Chanprasertyothin S., and Rojanasakul A. Acanthosis nigricans: clinical predictor of abnormal glucose tolerance in Asian women with polycystic ovary syndrome. Gynecol. Endocrinol. 21 3 (2005) 161-164
14. Fernandes A.R., de Sa Rosa e Silva A.C., Romao G.S., Pata M.C., and dos Reis R.M. Insulin resistance in adolescents with menstrual irregularities. J. Pediatr. Adolesc. Gynecol. 18 4 (2005) 269-274
15. Ibanez L., Valls C., Potau N., Marcos M.V., and de Zegher F. Polycystic ovary syndrome after precocious pubarche: ontogeny of the low-birthweight effect. Clin. Endocrinol. (Oxf.) 55 5 (2001) 667-672
16. Dewailly D. Physiopathology of polycystic ovary syndrome. Ann. Endocrinol. (Paris) 60 2 (1999) 123-130
17. Nelson V.L., Legro R.S., Strauss III J.F., and McAllister J.M. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol. Endocrinol. 13 6 (1999) 946-957
18. Nelson V.L., Qin Kn K.N., Rosenfield R.L., Wood J.R., Penning T.M., Legro R.S., et al. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 86 12 (2001) 5925-5933
19. Nelson-Degrave V.L., Wickenheisser J.K., Hendricks K.L., Asano T., Fujishiro M., Legro R.S., et al. Alterations in mitogen-activated protein kinase kinase and extracellular regulated kinase signaling in theca cells contribute to excessive androgen production in polycystic ovary syndrome. Mol. Endocrinol. 19 2 (2005) 379-390
20. Haisenleder D.J., Dalkin A.C., Ortolano G.A., Marshall J.C., and Shupnik M.A. A pulsatile gonadotropin-releasing hormone stimulus is required to increase transcription of the gonadotropin subunit genes: evidence for differential regulation of transcription by pulse frequency in vivo. Endocrinology 128 1 (1991) 509-517
21. Eagleson C.A., Gingrich M.B., Pastor C.L., Arora T.K., Burt C.M., Evans W.S., et al. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J. Clin. Endocrinol. Metab. 85 11 (2000) 4047-4052
22. Pache T.D., Chadha S., Gooren L.J., Hop W.C., Jaarsma K.W., Dommerholt H.B., et al. Ovarian morphology in long-term androgen-treated female to male transsexuals. A human model for the study of polycystic ovarian syndrome?. Histopathology 19 5 (1991) 445-452
23. Jonard S., and Dewailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum. Reprod. Update 10 2 (2004) 107-117
24. Willis D.S., Watson H., Mason H.D., Galea R., Brincat M., and Franks S. Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of anovulation. J. Clin. Endocrinol. Metab. 83 11 (1998) 3984-3991
25. Kuscu N.K., Koyuncu F., Ozbilgin K., Inan S., Tuglu I., and Karaer O. Insulin: does it induce follicular arrest in the rat ovary?. Gynecol. Endocrinol. 16 5 (2002) 361-364
26. Welt C.K., Taylor A.E., Fox J., Messerlian G.M., Adams J.M., and Schneyer A.L. Follicular arrest in polycystic ovary syndrome is associated with deficient inhibin A and B biosynthesis. J. Clin. Endocrinol. Metab. 90 10 (2005) 5582-5587
27. Fujiwara T., Sidis Y., Welt C., Lambert-Messerlian G., Fox J., Taylor A., et al. Dynamics of inhibin subunit and follistatin mRNA during development of normal and polycystic ovary syndrome follicles. J. Clin. Endocrinol. Metab. 86 9 (2001) 4206-4215
28. Florez J.C. Genetic susceptibility for polycystic ovary syndrome on chromosome 19: advances in the genetic dissection of complex reproductive traits. J. Clin. Endocrinol. Metab. 90 12 (2005) 6732-6734
29. Sam S., Legro R.S., Essah P.A., Apridonidze T., and Dunaif A. Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome. Proc. Natl. Acad. Sci. USA 103 18 (2006) 7030-7035
30. Leibel N.I., Baumann E.E., Kocherginsky M., and Rosenfield R.L. Relationship of adolescent polycystic ovary syndrome to parental metabolic syndrome. J. Clin. Endocrinol. Metab. 91 4 (2006) 1275-1283
31. Gonzalez F., Rote N.S., Minium J., and Kirwan J.P. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 91 1 (2006) 336-340
32. Carmina E., Orio F., Palomba S., Longo R.A., Cascella T., Colao A., et al. Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am. J. Med. 119 4 (2006) 356 (e1-6)
33. Lystedt E., Westergren H., Brynhildsen J., Lindh-Astrand L., Gustavsson J., Nystrom F., et al. Subcutaneous adipocytes from obese hyperinsulinemic women with polycystic ovary syndrome exhibit normal insulin sensitivity but reduced maximal insulin responsiveness. Eur. J. Endocrinol. 153 6 (2005) 831-835
34. Knochenhauer E.S., Key T.J., Kahsar-Miller M., Waggoner W., Boots L.R., and Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J. Clin. Endocrinol. Metab. 83 9 (1998) 3078-3082
35. Asuncion M., Calvo R.M., San Millan J.L., Sancho J., Avila S., and Escobar-Morreale H.F. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J. Clin. Endocrinol. Metab. 85 7 (2000) 2434-2438
36. Diamanti-Kandarakis E., Kouli C.R., Bergiele A.T., Filandra F.A., Tsianateli T.C., Spina G.G., et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J. Clin. Endocrinol. Metab. 84 11 (1999) 4006-4011
37. Kauffman R.P., Baker V.M., Dimarino P., Gimpel T., and Castracane V.D. Polycystic ovarian syndrome and insulin resistance in white and Mexican American women: a comparison of two distinct populations. Am. J. Obstet. Gynecol. 187 5 (2002) 1362-1369
38. Williamson K., Gunn A.J., Johnson N., and Milsom S.R. The impact of ethnicity on the presentation of polycystic ovarian syndrome. Aust. N. Z. J. Obstet. Gynaecol. 41 2 (2001) 202-206
39. Azziz R., and Kashar-Miller M.D. Family history as a risk factor for the polycystic ovary syndrome. J. Pediatr. Endocrinol. Metab. 13 Suppl 5 (2000) 1303-1306
40. Urbanek M., Legro R.S., Driscoll D.A., Azziz R., Ehrmann D.A., Norman R.J., et al. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc. Natl. Acad. Sci. USA 96 15 (1999) 8573-8578
41. Legro R.S., Driscoll D., Strauss III J.F., Fox J., and Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc. Natl. Acad. Sci. USA 95 25 (1998) 14956-14960
42. Ehrmann D.A., Sturis J., Byrne M.M., Karrison T., Rosenfield R.L., and Polonsky K.S. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J. Clin. Invest. 96 1 (1995) 520-527
43. Kahsar-Miller M.D., Nixon C., Boots L.R., Go R.C., and Azziz R. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil. Steril. 75 1 (2001) 53-58
44. Wood J.R., Nelson V.L., Ho C., Jansen E., Wang C.Y., Urbanek M., et al. The molecular phenotype of polycystic ovary syndrome (PCOS) theca cells and new candidate PCOS genes defined by microarray analysis. J. Biol. Chem. 278 29 (2003) 26380-26390
45. Draper N., Walker E.A., Bujalska I.J., Tomlinson J.W., Chalder S.M., Arlt W., et al. Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nat. Genet. 34 4 (2003) 434-439
46. Carmina E. Genetic and environmental aspect of polycystic ovary syndrome. J. Endocrinol. Invest. 26 11 (2003) 1151-1159
47. Roldan B., San Millan J.L., and Escobar-Morreale H.F. Genetic basis of metabolic abnormalities in polycystic ovary syndrome: implications for therapy. Am. J. Pharmacogenomics 4 2 (2004) 93-107
48. Luque-Ramirez M., San Millan J.L., and Escobar-Morreale H.F. Genomic variants in polycystic ovary syndrome. Clin. Chim. Acta 366 1-2 (2006) 14-26
49. Eisner J.R., Dumesic D.A., Kemnitz J.W., and Abbott D.H. Timing of prenatal androgen excess determines differential impairment in insulin secretion and action in adult female rhesus monkeys. J. Clin. Endocrinol. Metab. 85 3 (2000) 1206-1210
50. Eisner J.R., Dumesic D.A., Kemnitz J.W., Colman R.J., and Abbott D.H. Increased adiposity in female rhesus monkeys exposed to androgen excess during early gestation. Obes. Res. 11 2 (2003) 279-286
51. Eisner J.R., Barnett M.A., Dumesic D.A., and Abbott D.H. Ovarian hyperandrogenism in adult female rhesus monkeys exposed to prenatal androgen excess. Fertil. Steril. 77 1 (2002) 167-172
52. Abbott D.H., Dumesic D.A., and Franks S. Developmental origin of polycystic ovary syndrome - a hypothesis. J. Endocrinol. 174 1 (2002) 1-5
53. Xita N., and Tsatsoulis A. Review: fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies. J. Clin. Endocrinol. Metab. 91 5 (2006) 1660-1666
54. Glueck C.J., Papanna R., Wang P., Goldenberg N., and Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 52 7 (2003) 908-915
55. Ehrmann D.A., Liljenquist D.R., Kasza K., Azziz R., Legro R.S., and Ghazzi M.N. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 91 1 (2006) 48-53
56. Grundy S.M., Hansen B., Smith Jr. S.C., Cleeman J.I., and Kahn R.A. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 109 4 (2004) 551-556
57. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 25 (2002) 3143-3421
58. Sam S., and Dunaif A. Polycystic ovary syndrome: syndrome XX?. Trends Endocrinol. Metab. 14 8 (2003) 365-370
59. Apridonidze T., Essah P.A., Iuorno M.J., and Nestler J.E. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 90 4 (2005) 1929-1935
60. Sir-Petermann T., Hitchsfeld C., Maliqueo M., Codner E., Echiburu B., Gazitua R., et al. Birth weight in offspring of mothers with polycystic ovarian syndrome. Hum. Reprod. 20 8 (2005) 2122-2126
61. Vanky E., Salvesen K.A., Heimstad R., Fougner K.J., Romundstad P., and Carlsen S.M. Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Hum. Reprod. 19 8 (2004) 1734-1740
62. Meyer C., McGrath B.P., and Teede H.J. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J. Clin. Endocrinol. Metab. 90 10 (2005) 5711-5716
63. Kaushal R., Parchure N., Bano G., Kaski J.C., and Nussey S.S. Insulin resistance and endothelial dysfunction in the brothers of Indian subcontinent Asian women with polycystic ovaries. Clin. Endocrinol. (Oxf.) 60 3 (2004) 322-328
64. Yilmaz M., Bukan N., Ersoy R., Karakoc A., Yetkin I., Ayvaz G., et al. Glucose intolerance, insulin resistance and cardiovascular risk factors in first degree relatives of women with polycystic ovary syndrome. Hum. Reprod. 20 9 (2005) 2414-2420
65. Bruzeau J., Nicolas M.H., Bernard S., Moulin P., and Pugeat M. Metabolic syndrome and polycystic ovary syndrome. Journ. Annu. Diabetol. Hotel Dieu (2005) 103-111
66. Azziz R., Nicolas M.H., Bernard S., Moulin P., and Pugeat M. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J. Clin. Endocrinol. Metab. 86 4 (2001) 1626-1632
67. Conway G.S., Honour J.W., and Jacobs H.S. Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients. Clin. Endocrinol. (Oxf.) 30 4 (1989) 459-470
68. Franks S. Polycystic ovary syndrome: a changing perspective. Clin. Endocrinol. (Oxf.) 31 1 (1989) 87-120
69. Carmina E., Legro R.S., Stamets K., Lowell J., and Lobo R.A. Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. Hum. Reprod. 18 11 (2003) 2289-2293
70. Mokdad A.H., Ford E.S., Bowman B.A., Dietz W.H., Vinicor F., Bales V.S., et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289 1 (2003) 76-79
71. Legro R.S., Kunselman A.R., Dodson W.C., and Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J. Clin. Endocrinol. Metab. 84 1 (1999) 165-169
72. Ehrmann D.A., Barnes R.B., Rosenfield R.L., Cavaghan M.K., and Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22 1 (1999) 141-146
73. Krosnick A. The diabetes and obesity epidemic among the Pima Indians. N. J. Med. 97 8 (2000) 31-37
74. Dunaif A., Segal K.R., Futterweit W., and Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38 9 (1989) 1165-1174
75. Legro R.S., Gnatuk C.L., Kunselman A.R., and Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J. Clin. Endocrinol. Metab. 90 6 (2005) 3236-3242
76. Trolle B., and Lauszus F.F. Risk factors for glucose intolerance in Danish women with polycystic ovary syndrome. Acta Obstet. Gynecol. Scand. 84 12 (2005) 1192-1196
77. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr. Rev. 18 6 (1997) 774-800
78. Dunaif A., Wu X., Lee A., and Diamanti-Kandarakis E. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am. J. Physiol. Endocrinol. Metab. 281 2 (2001) 392-399
79. Polonsky K.S., Sturis J., and Bell G.I. Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. N. Engl. J. Med. 334 12 (1996) 777-783
80. Kahn S.E., Prigeon R.L., McCulloch D.K., Boyko E.J., Bergman R.N., Schwartz M.W., et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42 11 (1993) 1663-1672
81. Ehrmann D.A., Breda E., Cavaghan M.K., Bajramovic S., Imperial J., Toffolo G., et al. Insulin secretory responses to rising and falling glucose concentrations are delayed in subjects with impaired glucose tolerance. Diabetologia 45 4 (2002) 509-517
82. Ehrmann D.A., Breda E., Corcoran M.C., Cavaghan M.K., Imperial J., Toffolo G., et al. Impaired beta-cell compensation to dexamethasone-induced hyperglycemia in women with polycystic ovary syndrome. Am. J. Physiol. Endocrinol. Metab. 287 2 (2004) E241-E246
83. O'Meara N.M., Blackman J.D., Ehrmann D.A., Barnes R.B., Jaspan J.B., Rosenfield R.L., et al. Defects in beta-cell function in functional ovarian hyperandrogenism. J. Clin. Endocrinol. Metab. 76 5 (1993) 1241-1247
84. Dunaif A., and Finegood D.T. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 81 3 (1996) 942-947
85. Kousta E., Cela E., Lawrence N., Penny A., Millauer B., White D., et al. The prevalence of polycystic ovaries in women with a history of gestational diabetes. Clin. Endocrinol. (Oxf.) 53 4 (2000) 501-507
86. Zimmermann S., Phillips R.A., Dunaif A., Finegood D.T., Wilkenfeld C., Ardeljan M., et al. Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance. J. Clin. Endocrinol. Metab. 75 2 (1992) 508-513
87. Dahlgren E., Johansson S., Lindstedt G., Knutsson F., Oden A., Janson P.O., et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil. Steril. 57 3 (1992) 505-513
88. Dahlgren E., Janson P.O., Johansson S., Lapidus L., and Oden A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet. Gynecol. Scand. 71 8 (1992) 599-604
89. Kelly C.J., Speirs A., Gould G.W., Petrie J.R., Lyall H., and Connell J.M. Altered vascular function in young women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 87 2 (2002) 742-746
90. Paradisi G., Steinberg H.O., Shepard M.K., Hook G., and Baron A.D. Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 88 2 (2003) 576-580
91. Orio Jr. F., Palomba S., Cascella T., De Simone B., Di Biase S., Russo T., et al. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 89 9 (2004) 4588-4593
92. Orio Jr. F., Palomba S., Spinelli L., Cascella T., Tauchmanova L., Zullo F., et al. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J. Clin. Endocrinol. Metab. 89 8 (2004) 3696-3701
93. Yildiz B.O., Haznedaroglu I.C., Kirazli S., and Bayraktar M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J. Clin. Endocrinol. Metab. 87 8 (2002) 3871-3875
94. Christian R.C., Dumesic D.A., Behrenbeck T., Oberg A.L., Sheedy II P.F., and Fitzpatrick L.A. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 88 6 (2003) 2562-2568
95. Topcu S., Caliskan M., Gullu H., Ozcimen E.E., Erdogan D., Uckuyu A., et al. Do women with polycystic ovary syndrome really have predisposition to atherosclerosis?. Aust. N. Z. J. Obstet. Gynaecol. 46 2 (2006) 164-167
96. Orio Jr. F., Giallauria F., Palomba S., Cascella T., Manguso F., Vuolo L., et al. Cardiopulmonary impairment in young women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 91 8 (2006) 2967-2971
97. Ehrmann D.A., Schneider D.J., Sobel B.E., Cavaghan M.K., Imperial J., Rosenfield R.L., et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 82 7 (1997) 2108-2116
98. Atiomo W.U., Bates S.A., Condon J.E., Shaw S., West J.H., and Prentice A.G. The plasminogen activator system in women with polycystic ovary syndrome. Fertil. Steril. 69 2 (1998) 236-241
99. Dahlgren E., Janson P.O., Johansson S., Lapidus L., Lindstedt G., and Tengborn L. Hemostatic and metabolic variables in women with polycystic ovary syndrome. Fertil. Steril. 61 3 (1994) 455-460
100. Glueck C.J., Sieve L., Zhu B., and Wang P. Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome. Metabolism 55 3 (2006) 345-352
101. Kilicdag E.B., Bagis T., Zeyneloglu H.B., Tarim E., Aslan E., Haydardedeoglu B., et al. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. Hum. Reprod. 20 4 (2005) 894-899
102. Cagnacci A., Tirelli A., Renzi A., Paoletti A.M., and Volpe A. Effects of two different oral contraceptives on homocysteine metabolism in women with polycystic ovary syndrome. Contraception 73 4 (2006) 348-351
103. Talbott E., Guzick D., Clerici A., Berga S., Detre K., Weimer K., et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler. Thromb. Vasc. Biol. 15 7 (1995) 821-826
104. Talbott E.O., Zborowskii J.V., and Boudraux M.Y. Do women with polycystic ovary syndrome have an increased risk of cardiovascular disease? Review of the evidence. Minerva Ginecol. 56 1 (2004) 27-39
105. Wild S., Pierpoint T., Jacobs H., and McKeigue P. Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum. Fertil. (Camb.) 3 2 (2000) 101-105
106. Legro R.S. Polycystic ovary syndrome and cardiovascular disease: a premature association?. Endocr. Rev. 24 3 (2003) 302-312
107. Gopal M., Duntley S., Uhles M., and Attarian H. The role of obesity in the increased prevalence of obstructive sleep apnea syndrome in patients with polycystic ovarian syndrome. Sleep Med. 3 5 (2002) 401-404
108. Vgontzas A.N., Legro R.S., Bixler E.O., Grayev A., Kales A., and Chrousos G.P. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J. Clin. Endocrinol. Metab. 86 2 (2001) 517-520
109. Fogel R.B., Malhotra A., Pillar G., Pittman S.D., Dunaif A., and White D.P. Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 86 3 (2001) 1175-1180
110. Tasali E., Van Cauter E., and Ehrmann D.A. Relationships between sleep disordered breathing and glucose metabolism in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 91 1 (2006) 36-42
111. Balen A. Polycystic ovary syndrome and cancer. Hum. Reprod. Update 7 6 (2001) 522-525
112. Hardiman P., Pillay O.C., and Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet 361 9371 (2003) 1810-1812
113. Pillay O.C., Te Fong L.F., Crow J.C., Benjamin E., Mould T., Atiomo W., et al. The association between polycystic ovaries and endometrial cancer. Hum. Reprod. 21 4 (2006) 924-929
114. Hull M.G. Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecol. Endocrinol. 1 3 (1987) 235-245
115. Hart R., Hickey M., and Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 18 5 (2004) 671-683
116. Doi S.A., Towers P.A., Scott C.J., and Al-Shoumer K.A. PCOS: an ovarian disorder that leads to dysregulation in the hypothalamic-pituitary-adrenal axis?. Eur. J. Obstet. Gynecol. Reprod. Biol. 118 1 (2005) 4-16
117. Jakubowicz D.J., Iuorno M.J., Jakubowicz S., Roberts K.A., and Nestler J.E. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 87 2 (2002) 524-529
118. Norman R.J. Editorial: Metformin--comparison with other therapies in ovulation induction in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 89 10 (2004) 4797-4800
119. Norman R.J., Wang J.X., and Hague W. Should we continue or stop insulin sensitizing drugs during pregnancy?. Curr. Opin. Obstet. Gynecol. 16 3 (2004) 245-250
120. Rai R., Backos M., Rushworth F., and Regan L. Polycystic ovaries and recurrent miscarriage--a reappraisal. Hum. Reprod. 15 3 (2000) 612-615
121. Porter T.F., and Scott J.R. Evidence-based care of recurrent miscarriage. Best Pract. Res. Clin. Obstet. Gynaecol. 19 1 (2005) 85-101
122. Li T.C. Recurrent miscarriage: principles of management. Hum. Reprod. 13 2 (1998) 478-482
123. Regan L., Owen E.J., and Jacobs H.S. Hypersecretion of luteinising hormone, infertility, and miscarriage. Lancet 336 8724 (1990) 1141-1144
124. Hamilton-Fairley D., Kiddy D., Watson H., Paterson C., and Franks S. Association of moderate obesity with a poor pregnancy outcome in women with polycystic ovary syndrome treated with low dose gonadotrophin. Br. J. Obstet. Gynaecol. 99 2 (1992) 128-131
125. Fedorcsak P., Storeng R., Dale P.O., Tanbo T., and Abyholm T. Obesity is a risk factor for early pregnancy loss after IVF or ICSI. Acta Obstet. Gynecol. Scand. 79 1 (2000) 43-48
126. Fedorcsak P., Dale P.O., Storeng R., Ertzeid G., Bjercke S., Oldereid N., et al. Impact of overweight and underweight on assisted reproduction treatment. Hum. Reprod. 19 11 (2004) 2523-2528
127. Patel S.M., and Nestler J.E. Fertility in polycystic ovary syndrome. Endocrinol. Metab. Clin. North Am. 35 1 (2006) 137-155 (vii)
128. Glueck C.J., Wang P., Fontaine R.N., Sieve-Smith L., Tracy T., and Moore S.K. Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism 48 12 (1999) 1589-1595
129. Jakubowicz D.J., Essah P.A., Seppala M., Jakubowicz S., Baillargeon J.P., Koistinen R., et al. Reduced serum glycodelin and insulin-like growth factor-binding protein-1 in women with polycystic ovary syndrome during first trimester of pregnancy. J. Clin. Endocrinol. Metab. 89 2 (2004) 833-839
130. Boomsma C.M., Eijkemans M.J., Hughes E.G., Visser G.H., Fauser B.C., and Macklon N.S. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome (2006), Hum Reprod Update
131. Hoeger K.M., Kochman L., Wixom N., Craig K., Miller R.K., and Guzick D.S. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil. Steril. 82 2 (2004) 421-429
132. Huber-Buchholz M.M., Carey D.G., and Norman R.J. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J. Clin. Endocrinol. Metab. 84 4 (1999) 1470-1474
133. Moran L.J., Noakes M., Clifton P.M., Tomlinson L., Galletly C., and Norman R.J. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 88 2 (2003) 812-819
134. Nestler J.E., Jakubowicz D.J., Evans W.S., and Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N. Engl. J. Med. 338 26 (1998) 1876-1880
135. Kuhl H. Comparative pharmacology of newer progestogens. Drugs 51 2 (1996) 188-215
136. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 62 1 (2000) 29-38
137. Guido M., Romualdi D., Giuliani M., Suriano R., Selvaggi L., Apa R., et al. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J. Clin. Endocrinol. Metab. 89 6 (2004) 2817-2823
138. Diamanti-Kandarakis E., Baillargeon J.P., Iuorno M.J., Jakubowicz D.J., and Nestler J.E. A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J. Clin. Endocrinol. Metab. 88 5 (2003) 1927-1932
139. Golland I.M., and Elstein M.E. Results of an open one-year study with Diane-35 in women with polycystic ovarian syndrome. Ann. N. Y. Acad. Sci. 687 (1993) 263-271
140. Spritzer P.M., Lisboa K.O., Mattiello S., and Lhullier F. Spironolactone as a single agent for long-term therapy of hirsute patients. Clin. Endocrinol. (Oxf.) 52 5 (2000) 587-594
141. Muderris I.I., Bayram F., and Guven M. Treatment of hirsutism with lowest-dose flutamide (62.5 mg/day). Gynecol. Endocrinol. 14 1 (2000) 38-41
142. Moghetti P., Tosi F., Tosti A., Negri C., Misciali C., Perrone F., et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J. Clin. Endocrinol. Metab. 85 1 (2000) 89-94
143. Gambineri A., Pelusi C., Genghini S., Morselli-Labate A.M., Cacciari M., Pagotto U., et al. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf.) 60 2 (2004) 241-249
144. Ehrmann D.A., Rosenfield R.L., Barnes R.B., Brigell D.F., and Sheikh Z. Detection of functional ovarian hyperandrogenism in women with androgen excess. N. Engl. J. Med. 327 3 (1992) 157-162
145. Azziz R., Black V., Hines G.A., Fox L.M., and Boots L.R. Adrenal androgen excess in the polycystic ovary syndrome: sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis. J. Clin. Endocrinol. Metab. 83 7 (1998) 2317-2323
146. Azziz R., Black V.Y., Knochenhauer E.S., Hines G.A., and Boots L.R. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level. J. Clin. Endocrinol. Metab. 84 3 (1999) 946-950
147. Liang T., Heiss C.E., Ostrove S., Rasmusson G.H., and Cheung A. Binding of a 4-methyl-4-aza-steroid to 5 alpha-reductase of rat liver and prostate microsomes. Endocrinology 112 4 (1983) 1460-1468
148. Falsetti L., Gambera A., Legrenzi L., Iacobello C., and Bugari G. Comparison of finasteride versus flutamide in the treatment of hirsutism. Eur. J. Endocrinol. 141 4 (1999) 361-367
149. Stamets K., Taylor D.S., Kunselman A., Demers L.M., Pelkman C.L., and Legro R.S. A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. Fertil. Steril. 81 3 (2004) 630-637
150. Douglas C.C., Gower B.A., Darnell B.E., Ovalle F., Oster R.A., and Azziz R. Role of diet in the treatment of polycystic ovary syndrome. Fertil. Steril. 85 3 (2006) 679-688
151. Mansfield R., Galea R., Brincat M., Hole D., and Mason H. Metformin has direct effects on human ovarian steroidogenesis. Fertil. Steril. 79 4 (2003) 956-962
152. Attia G.R., Rainey W.E., and Carr B.R. Metformin directly inhibits androgen production in human thecal cells. Fertil. Steril. 76 3 (2001) 517-524
153. Eisenhardt S., Schwarzmann N., Henschel V., Germeyer A., von Wolff M., Hamann A., et al. Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double-blind, placebo-controlled trial. J. Clin. Endocrinol. Metab. 91 3 (2006) 946-952
154. Banaszewska B., Duleba A.J., Spaczynski R.Z., and Pawelczyk L. Lipids in polycystic ovary syndrome: role of hyperinsulinemia and effects of metformin. Am. J. Obstet. Gynecol. 194 5 (2006) 1266-1272
155. Crave J.C., Fimbel S., Lejeune H., Cugnardey N., Dechaud H., and Pugeat M. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J. Clin. Endocrinol. Metab. 80 7 (1995) 2057-2062
156. Mitwally M.F., Witchel S.F., and Casper R.F. Troglitazone: a possible modulator of ovarian steroidogenesis. J. Soc. Gynecol. Investig. 9 3 (2002) 163-167
157. Dunaif A., Scott D., Finegood D., Quintana B., and Whitcomb R. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 81 9 (1996) 3299-3306
158. Rautio K., Tapanainen J.S., Ruokonen A., and Morin-Papunen L.C. Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. Hum. Reprod. 21 6 (2006) 1400-1407
159. Ghazeeri G., Kutteh W.H., Bryer-Ash M., Haas D., and Ke R.W. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil. Steril. 79 3 (2003) 562-566
160. Belli S.H., Graffigna M.N., Oneto A., Otero P., Schurman L., and Levalle O.A. Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertil. Steril. 81 3 (2004) 624-629
161. Romualdi D., Guido M., Ciampelli M., Giuliani M., Leoni F., Perri C., et al. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum. Reprod. 18 6 (2003) 1210-1218
162. Ortega-Gonzalez C., Luna S., Hernandez L., Crespo G., Aguayo P., Arteaga-Troncoso G., et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 90 3 (2005) 1360-1365
163. Yilmaz M., Karakoc A., Toruner F.B., Cakir N., Tiras B., Ayvaz G., et al. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Gynecol. Endocrinol. 21 3 (2005) 154-160
164. Legro R.S., Finegood D., and Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 83 8 (1998) 2694-2698
165. Poretsky L., Cataldo N.A., Rosenwaks Z., and Giudice L.C. The insulin-related ovarian regulatory system in health and disease. Endocr. Rev. 20 4 (1999) 535-582
166. Homburg R. Adverse effects of luteinizing hormone on fertility: fact or fantasy. Baillieres Clin. Obstet. Gynaecol. 12 4 (1998) 555-563
167. Dale P.O., Tanbo T., Ertzeid G., Bjercke S., Oldereid N., Fedorcsak P., et al. The impact of insulin resistance on the outcome of laparoscopic ovarian electrocautery in infertile women with the polycystic ovary syndrome. Gynecol. Endocrinol. 19 4 (2004) 182-189
168. White D.M., Polson D.W., Kiddy D., Sagle P., Watson H., Gilling-Smith C., et al. Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. J. Clin. Endocrinol. Metab. 81 11 (1996) 3821-3824
169. Kiddy D.S., Hamilton-Fairley D., Bush A., Short F., Anyaoku V., Reed M.J., et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf.) 36 1 (1992) 105-111
170. Pasquali R., Antenucci D., Casimirri F., Venturoli S., Paradisi R., Fabbri R., et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J. Clin. Endocrinol. Metab. 68 1 (1989) 173-179
171. Clark A.M., Ledger W., Galletly C., Tomlinson L., Blaney F., Wang X., et al. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum. Reprod. 10 10 (1995) 2705-2712
172. Homburg R. The management of infertility associated with polycystic ovary syndrome. Reprod. Biol. Endocrinol. 1 (2003) 109
173. Boothroyd C., and Yazdani A. Higher-order multiple pregnancy associated with metformin in women with polycystic ovary syndrome: two cases and review of the literature. Fertil. Steril. 85 1 (2006) 227
174. McCarthy E.A., Walker S.P., McLachlan K., Boyle J., and Permezel M. Metformin in obstetric and gynecologic practice: a review. Obstet. Gynecol. Surv. 59 2 (2004) 118-127
175. Hellmuth E., Damm P., and Molsted-Pedersen L. Oral hypoglycaemic agents in 118 diabetic pregnancies. Diabet. Med. 17 7 (2000) 507-511
176. Lord J.M., Fligh I.H.T., and Norman R.J. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 327 7421 (2003) 951-953
177. Kashyap S., Wells G.A., and Rosenwaks Z. Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome. Hum. Reprod. 19 11 (2004) 2474-2483
178. Tang T., Glanville J., Hayden C.J., White D., Barth J.H., and Balen A.H. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum. Reprod. 21 1 (2006) 80-89
179. Moll E., Bossuyt P.M., Korevaar J.C., Lambalk C.B., and van der Veen F. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ 332 7556 (2006) 1485
180. Legro R.S., Barnhart H.X., Schlaff W.D., Carr B.R., Diamond M.P., Carson S.A., et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N. Engl. J. Med. 356 6 (2007) 551-566
181. Rouzi A.A., and Ardawi M.S. A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome. Fertil. Steril. 85 2 (2006) 428-435
182. Palomba S., Orio Jr. F., Nardo L.G., Falbo A., Russo T., Corea D., et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial. J. Clin. Endocrinol. Metab. 89 10 (2004) 4801-4809
183. Carmina E., and Lobo R.A. Does metformin induce ovulation in normoandrogenic anovulatory women?. Am. J. Obstet. Gynecol. 191 5 (2004) 1580-1584
184. Baillargeon J.P., Jakubowicz D.J., Iuorno M.J., Jakubowicz S., and Nestler J.E. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil. Steril. 82 4 (2004) 893-902
185. Palomba S., Orio Jr. F., Falbo A., Manguso F., Russo T., Cascella T., et al. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 90 7 (2005) 4068-4074
186. Meenakumari K.J., Agarwal S., Krishna A., and Pandey L.K. Effects of metformin treatment on luteal phase progesterone concentration in polycystic ovary syndrome. Braz. J. Med. Biol. Res. 37 11 (2004) 1637-1644
187. Lee M.S., Kang S.K., Lee B.C., and Hwang W.S. The Beneficial Effects of Insulin and Metformin on in vitro Developmental Potential of Porcine Oocytes and Embryos. Biol. Reprod. (2005)
188. Palomba S., Russo T., Orio Jr. F., Falbo A., Manguso F., Cascella T., et al. Uterine effects of metformin administration in anovulatory women with polycystic ovary syndrome. Hum. Reprod. 21 2 (2006) 457-465
189. Glueck C.J., Wang P., Goldenberg N., and Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum. Reprod. 17 11 (2002) 2858-2864
190. Thatcher S.S., and Jackson E.M. Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin. Fertil. Steril. 85 4 (2006) 1002-1009
191. Heard M.J., Pierce A., Carson S.A., and Buster J.E. Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome. Fertil. Steril. 77 4 (2002) 669-673
192. Glueck C.J., Wang P., Goldenberg N., and Sieve L. Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin, metformin. Clin. Appl. Thromb. Hemost. 10 4 (2004) 323-334
193. Palomba S., Orio Jr. F., Falbo A., Russo T., Tolino A., and Zullo F. Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome. Fertil. Steril. 84 3 (2005) 761-765
194. Palomba S., Falbo A., Orio Jr. F., Manguso F., Russo T., Tolino A., et al. A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination (2005), Hum Reprod
195. Tasdemir S., Ficicioglu C., Yalti S., Gurbuz B., Basaran T., and Yildirim G. The effect of metformin treatment to ovarian response in cases with PCOS. Arch. Gynecol. Obstet. 269 2 (2004) 121-124
196. De Leo V., la Marca A., Ditto A., Morgante G., and Cianci A. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertil. Steril. 72 2 (1999) 282-285
197. Kjotrod S.B., von During V., and Carlsen S.M. Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Hum. Reprod. 19 6 (2004) 1315-1322
198. Onalan G., Pabuccu R., Goktolga U., Ceyhan T., Bagis T., and Cincik M. Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertil. Steril. 84 3 (2005) 798-801
199. Tang T., Glanville J., Orsi N., Barth J.H., and Balen A.H. The use of metformin for women with PCOS undergoing IVF treatment. Hum. Reprod. 21 6 (2006) 1416-1425
200. Costello M.F., Chapman M., and Conway U. A systematic review and meta-analysis of randomized controlled trials on metformin co-administration during gonadotrophin ovulation induction or IVF in women with polycystic ovary syndrome. Hum. Reprod. 21 6 (2006) 1387-1399
201. Gysler M., March C.M., Mishell Jr. D.R., and Bailey E.J. A decade's experience with an individualized clomiphene treatment regimen including its effect on the postcoital test. Fertil. Steril. 37 2 (1982) 161-167
202. Macgregor A.H., Johnson J.E., and Bunde C.A. Further clinical experience with clomiphene citrate. Fertil. Steril. 19 4 (1968) 616-622
203. Imani B., Eijkemans M.J., te Velde E.R., Habbema J.D., and Fauser B.C. A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Fertil. Steril. 77 1 (2002) 91-97
204. Imani B., Eijkemans M.J., te Velde E.R., Habbema J.D., and Fauser B.C. Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J. Clin. Endocrinol. Metab. 83 7 (1998) 2361-2365
205. Homburg R., Armar N.A., Eshel A., Adams J., and Jacobs H.S. Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome. BMJ 297 6655 (1988) 1024-1026
206. Lopez E., Gunby J., Daya S., Parrilla J.J., Abad L., and Balasch J. Ovulation induction in women with polycystic ovary syndrome: randomized trial of clomiphene citrate versus low-dose recombinant FSH as first line therapy. Reprod. Biomed. Online 9 4 (2004) 382-390
207. Agarwal S.K., and Buyalos R.P. Corpus luteum function and pregnancy rates with clomiphene citrate therapy: comparison of human chorionic gonadotrophin-induced versus spontaneous ovulation. Hum. Reprod. 10 2 (1995) 328-331
208. Diamant Y.Z., and Evron S. Induction of ovulation by combined clomiphene citrate and dexamethasone treatment in clomiphene citrate nonresponders. Eur. J. Obstet. Gynecol. Reprod. Biol. 11 5 (1981) 335-340
209. Daly D.C., Walters C.A., Soto-Albors C.E., Tohan N., and Riddick D.H. A randomized study of dexamethasone in ovulation induction with clomiphene citrate. Fertil. Steril. 41 6 (1984) 844-848
210. Mitwally M.F., and Casper R.F. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil. Steril. 75 2 (2001) 305-309
211. Mitwally M.F., and Casper R.F. Aromatase inhibition improves ovarian response to follicle-stimulating hormone in poor responders. Fertil. Steril. 77 4 (2002) 776-780
212. Elnashar A., Fouad H., Eldosoky M., and Saeid N. Letrozole induction of ovulation in women with clomiphene citrate-resistant polycystic ovary syndrome may not depend on the period of infertility, the body mass index, or the luteinizing hormone/follicle-stimulating hormone ratio. Fertil. Steril. 85 2 (2006) 511-513
213. Stein. Am. J. Obstet. Gynecol. 38 (1939) 465-473
214. Fernandez H., Watrelot A., Alby J.D., Kadoch J., Gervaise A., deTayrac R., et al. Fertility after ovarian drilling by transvaginal fertiloscopy for treatment of polycystic ovary syndrome. J. Am. Assoc. Gynecol. Laparosc. 11 3 (2004) 374-378
215. Fernandez H., Alby J.D., Gervaise A., de Tayrac R., and Frydman R. Operative transvaginal hydrolaparoscopy for treatment of polycystic ovary syndrome: a new minimally invasive surgery. Fertil. Steril. 75 3 (2001) 607-611
216. Fernandez H., Gervaise A., Alby J.D., and Kadoch J. Ovarian drilling for surgical approach of polycystic ovary syndrome. Gynecol. Obstet. Fertil. 31 3 (2003) 207-213
217. Malkawi H.Y., and Qublan S. Laparoscopic ovarian drilling in the treatment of polycystic ovary syndrome: how many punctures per ovary are needed to improve the reproductive outcome?. J. Obstet. Gynaecol. Res. 31 2 (2005) 115-119
218. Amer S.A., Li T.C., and Cooke I.D. A prospective dose-finding study of the amount of thermal energy required for laparoscopic ovarian diathermy. Hum. Reprod. 18 8 (2003) 1693-1698
219. Api M., Gorgen H., and Cetin A. Laparoscopic ovarian drilling in polycystic ovary syndrome. Eur. J. Obstet. Gynecol. Reprod. Biol. 119 1 (2005) 76-81
220. Kandil M., and Selim M. Hormonal and sonographic assessment of ovarian reserve before and after laparoscopic ovarian drilling in polycystic ovary syndrome. BJOG 112 10 (2005) 1427-1430
221. Kucuk M., and Kilic-Okman T. Hormone profiles and clinical outcome after laparoscopic ovarian drilling in women with polycystic ovary syndrome. Med. Sci. Monit. 11 1 (2005) CR29-CR34
222. Amer S.A., Li T.C., and Ledger W.L. Ovulation induction using laparoscopic ovarian drilling in women with polycystic ovarian syndrome: predictors of success. Hum. Reprod. 19 8 (2004) 1719-1724
223. Gjonnaess H. Ovarian electrocautery in the treatment of women with polycystic ovary syndrome (PCOS). Factors affecting the results. Acta Obstet. Gynecol. Scand. 73 5 (1994) 407-412
224. van Wely M., Bayram N., van der Veen F., and Bossuyt P.M. Predictors for treatment failure after laparoscopic electrocautery of the ovaries in women with clomiphene citrate resistant polycystic ovary syndrome. Hum. Reprod. 20 4 (2005) 900-905
225. Donesky B.W., and Adashi E.Y. Surgical ovulation induction: the role of ovarian diathermy in polycystic ovary syndrome. Baillieres Clin. Endocrinol. Metab. 10 2 (1996) 293-309
226. Farquhar C., Vandekerckhove P., and Lilford R. Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst. Rev. 4 (2001) (CD001122)
227. Bayram N., van Wely M., Kaaijk E.M., Bossuyt P.M., and van der Veen F. Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomised controlled trial. BMJ 328 7433 (2004) 192
228. van Wely M., Bayram N., van der Veen F., and Bossuyt P.M. An economic comparison of a laparoscopic electrocautery strategy and ovulation induction with recombinant FSH in women with clomiphene citrate-resistant polycystic ovary syndrome. Hum. Reprod. 19 8 (2004) 1741-1745
229. Abdel Gadir A., Mowafi R.S., Alnaser H.M., Alrashid A.H., Alonezi O.M., and Shaw R.W. Ovarian electrocautery versus human menopausal gonadotrophins and pure follicle stimulating hormone therapy in the treatment of patients with polycystic ovarian disease. Clin. Endocrinol. (Oxf.) 33 5 (1990) 585-592
230. Gjonnaess H. Late endocrine effects of ovarian electrocautery in women with polycystic ovary syndrome. Fertil. Steril. 69 4 (1998) 697-701
231. Tozer A.J., Al-Shawaf T., Zosmer A., Hussain S., Wilson C., Lower A.M., et al. Does laparoscopic ovarian diathermy affect the outcome of IVF-embryo transfer in women with polycystic ovarian syndrome? A retrospective comparative study. Hum. Reprod. 16 1 (2001) 91-95
232. Tummon I., Gavrilova-Jordan L., Allemand M.C., and Session D. Polycystic ovaries and ovarian hyperstimulation syndrome: a systematic review*. Acta Obstet. Gynecol. Scand. 84 7 (2005) 611-616
233. Insler V. Gonadotropin therapy: new trends and insights. Int. J. Fertil. 33 2 (1988) 85-86 (89-97)
234. Van Der Meer M., Hompes P.G., De Boer J.A., Schats R., and Schoemaker J. Cohort size rather than follicle-stimulating hormone threshold level determines ovarian sensitivity in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 83 2 (1998) 423-426
235. Seibel M.M., Kamrava M.M., McArdle C., and Taymor M.L. Treatment of polycystic ovary disease with chronic low-dose follicle stimulating hormone: biochemical changes and ultrasound correlation. Int. J. Fertil. 29 1 (1984) 39-43
236. Polson D.W., Mason H.D., Saldahna M.B., and Franks S. Ovulation of a single dominant follicle during treatment with low-dose pulsatile follicle stimulating hormone in women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf.) 26 2 (1987) 205-212
237. Schoot D.C., Hop W.C., de Jong F.H., van Dessel T.J., and Fauser B.C. Initial estradiol response predicts outcome of exogenous gonadotropins using a step-down dose regimen for induction of ovulation in polycystic ovary syndrome. Fertil. Steril. 64 6 (1995) 1081-1087
238. van Dessel H.J., Schoot B.C., Schipper I., Dahl K.D., and Fauser B.C. Circulating immunoreactive and bioactive follicle stimulating hormone concentrations in anovulatory infertile women and during gonadotrophin induction of ovulation using a decremental dose regimen. Hum. Reprod. 11 3 (1996) 478-485
239. Hamilton-Fairley D., and Franks S. Common problems in induction of ovulation. Baillieres Clin. Obstet. Gynaecol. 4 3 (1990) 609-625
240. Homburg R., Levy T., and Ben-Rafael Z. A comparative prospective study of conventional regimen with chronic low-dose administration of follicle-stimulating hormone for anovulation associated with polycystic ovary syndrome. Fertil. Steril. 63 4 (1995) 729-733
241. Hedon B., Hugues J.N., Emperaire J.C., Chabaud J.J., Barbereau D., Boujenah A., et al. A comparative prospective study of a chronic low dose versus a conventional ovulation stimulation regimen using recombinant human follicle stimulating hormone in anovulatory infertile women. Hum. Reprod. 13 10 (1998) 2688-2692
242. Homburg R., and Howles C.M. Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements. Hum. Reprod. Update 5 5 (1999) 493-499
243. van Santbrink E.J., and Fauser B.C. Urinary follicle-stimulating hormone for normogonadotropic clomiphene-resistant anovulatory infertility: prospective, randomized comparison between low dose step-up and step-down dose regimens. J. Clin. Endocrinol. Metab. 82 11 (1997) 3597-3602
244. Christin-Maitre S., and Hugues J.N. A comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome. Hum. Reprod. 18 8 (2003) 1626-1631
245. Homburg R., Berkowitz D., Levy T., Feldberg D., Ashkenazi J., and Ben-Rafael Z. In vitro fertilization and embryo transfer for the treatment of infertility associated with polycystic ovary syndrome. Fertil. Steril. 60 5 (1993) 858-863
246. Homburg R., Levy T., Berkovitz D., Farchi J., Feldberg D., Ashkenazi J., et al. Gonadotropin-releasing hormone agonist reduces the miscarriage rate for pregnancies achieved in women with polycystic ovarian syndrome. Fertil. Steril. 59 3 (1993) 527-531
247. Homburg R., Eshel A., Kilborn J., Adams J., and Jacobs H.S. Combined luteinizing hormone releasing hormone analogue and exogenous gonadotrophins for the treatment of infertility associated with polycystic ovaries. Hum. Reprod. 5 1 (1990) 32-35
248. van der Meer M., Hompes P.G., Scheele F., Schoute E., Popp-Snijders C., and Schoemaker J. The importance of endogenous feedback for monofollicular growth in low-dose step-up ovulation induction with follicle-stimulating hormone in polycystic ovary syndrome: a randomized study. Fertil. Steril. 66 4 (1996) 571-576
249. Scheele F., Hompes P.G., van der Meer M., Schoute E., and Schoemaker J. The effects of a gonadotrophin-releasing hormone agonist on treatment with low dose follicle stimulating hormone in polycystic ovary syndrome. Hum. Reprod. 8 5 (1993) 699-704
250. Elkind-Hirsch K.E., Webster B.W., Brown C.P., and Vernon M.W. Concurrent ganirelix and follitropin beta therapy is an effective and safe regimen for ovulation induction in women with polycystic ovary syndrome. Fertil. Steril. 79 3 (2003) 603-607
251. Heijnen E.M., Eijkemans M.J., Hughes E.G., Laven J.S., Macklon N.S., and Fauser B.C. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Hum. Reprod. Update 12 1 (2006) 13-21
252. Child T.J., Phillips S.J., Abdul-Jalil A.K., Gulekli B., and Tan S.L. A comparison of in vitro maturation and in vitro fertilization for women with polycystic ovaries. Obstet. Gynecol. 100 4 (2002) 665-670
253. Cha K.Y. Pregnancy after in vitro fertilization of human follicular oocytes collected from nonstimulated cycles, their culture in vitro and their transfer in a donor oocyte program. Fertil. Steril. 55 1 (1991) 109-113
254. Chian R.C., Buckett W.M., and Tan S.L. In-vitro maturation of human oocytes. Reprod. Biomed. Online 8 2 (2004) 148-166
255. Cha K.Y., Chung H.M., Lee D.R., Kwon H., Chung M.K., Park L.S., et al. Obstetric outcome of patients with polycystic ovary syndrome treated by in vitro maturation and in vitro fertilization-embryo transfer. Fertil. Steril. 83 5 (2005) 1461-1465
256. Cha K.Y., Han S.Y., Chung H.M., Choi D.H., Lim J.M., Lee W.S., et al. Pregnancies and deliveries after in vitro maturation culture followed by in vitro fertilization and embryo transfer without stimulation in women with polycystic ovary syndrome. Fertil. Steril. 73 5 (2000) 978-983
257. Soderstrom-Anttila V., Makinen S., Tuuri T., and Suikkari A.M. Favourable pregnancy results with insemination of in vitro matured oocytes from unstimulated patients. Hum. Reprod. 20 6 (2005) 1534-1540
258. Mikkelsen A.L. Strategies in human in-vitro maturation and their clinical outcome. Reprod. Biomed. Online 10 5 (2005) 593-599
259. MacDougall M.J., Tan S.L., Balen A., and Jacobs H.S. A controlled study comparing patients with and without polycystic ovaries undergoing in-vitro fertilization. Hum. Reprod. 8 2 (1993) 233-237
260. Child T.J., Abdul-Jalil A.K., Gulekli B., and Tan S.L. In vitro maturation and fertilization of oocytes from unstimulated normal ovaries, polycystic ovaries, and women with polycystic ovary syndrome. Fertil. Steril. 76 5 (2001) 936-942